부산대학교 도서관

Cyfuse Biomedical K.K. is a R&D venture company established in 2010 aiming at industrialization of its 3D cellular products for regenerative medicine based on innovative 3D cell stacking technology, and has newly listed on the Growth Market of the Tokyo Stock Exchange in December 2022. We are developing 3D cellular products consisted of only human cells through our unique platform technology created from the fusion of two disparate technologies; engineering and biology. Three pipelines aiming for approval as products for regenerative medicine have already advanced to the stage of human clinical trials, and are expected to implemented in society in the near future. In addition, we also have been developing functional cellular devices (FCD) using our core technology, the Kenzan method, and have begun marketing FCD as support tools that contribute to the development of new drugs. We will introduce in detail our contribution to the medical field that we are aiming for, with specific examples, also referring to the unique additive manufacturing (AM) technology that supports the realization of our cellular products as above.